Repligen AIDS vaccine work
Executive Summary
Firm has discovered that a vaccine consisting of a fragment of a protein of the HTLV-III virus, gp 120, can produce neutralizing antibodies against AIDS infection in animals. Repligen said the protein section can be inexpensively mass produced using genetically engineered bacteria. Repligen is working in collaboration with Centocor, Duke University and the National Cancer Institute. NCI said it has begun testing the experimental vaccine in chimpanzees.